menu
    • menu
    [{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"QBECO SSI","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"QBKPN","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ NRC IRAP"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"QBECO SSI","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Qbeco","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Health Canada","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"QBKPN","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Health Canada","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Health Canada"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"QBECO-SSI","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Karolinska Institute"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Accelerating Clinical Trial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"QBECO","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qu Biologics Inc \/ Accelerating Clinical Trial","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Accelerating Clinical Trial"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Natural Sciences and Engineering Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"QBSAU","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Natural Sciences and Engineering Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Qu Biologics Inc \/ Natural Sciences and Engineering Council of Canada"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"QBECO SSI","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Foundation Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Qu Biologics Inc

    Menu

    Qu Biologics Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Foundation Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Qu Biologics And Foundation Medicine Partner For Colorectal Cancer Care

                            Details : The partnership aims to impact the care of patients with late-stage colorectal cancer undergoing surgery in a Phase II trial assessing QBECO SSI in reducing post-operative immune suppression.

                            Brand Name : QBECO SSI

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Foundation Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBSAU

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Natural Sciences and Engineering Council of Canada

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding

                            Details : The proceeds will support Qu Biologics’ preclinical and translational research activities aimed at expanding the portfolio of disease indications, including QBSAU, for the treatment of melanoma.

                            Brand Name : QBSAU

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 11, 2024

                            Lead Product(s) : QBSAU

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Natural Sciences and Engineering Council of Canada

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Accelerating Clinical Trial

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial

                            Details : The net proceeds will be used to fund the Phase 2 clinical trial in late-stage colon cancer evaluating QBECO, an SSI designed to restore innate immune responses in the gastrointestinal tract and related organs, including the liver.

                            Brand Name : QBECO

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : QBECO

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Accelerating Clinical Trial

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO-SSI

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of...

                            Details : QBECO-SSI treatment, which is designed to restore normal innate immune function, immune homeostasis, and barrier function in the GI tract, provides a novel potentially transformative alternative to immunosuppressive therapies for patients living with IBD...

                            Brand Name : QBECO-SSI

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : QBECO-SSI

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBKPN SSI

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : National Research Council of Canada Industrial Research Assistance Program

                            Deal Size : $6.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Functi...

                            Details : QBKPN SSI is designed to reprogram the functional competence of immune cells to fix the immune dysregulation that typically develops with aging, providing broad immune protection, not only against COVID-19.

                            Brand Name : QBKPN SSI

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : QBKPN SSI

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : National Research Council of Canada Industrial Research Assistance Program

                            Deal Size : $6.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO-SSI

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Dis...

                            Details : QBECO SSI treatment overcomes both cancer-induced and the more profound surgery-induced immune suppression through innate immune training and natural killer cell (NK cell) activation resulting in clearance of cancer cells in the targeted organ.

                            Brand Name : QBECO-SSI

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 26, 2022

                            Lead Product(s) : QBECO-SSI

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBKPN

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Health Canada

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Funct...

                            Details : QBKPN, a first-in-class innate immune modulator that enhances lung immunity, the treatment can improve the innate immune dysfunction that is present in the context of aging, inflammatory lung diseases, and lung cancer.

                            Brand Name : QBKPN

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 20, 2022

                            Lead Product(s) : QBKPN

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Health Canada

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Qbeco

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Qu Biologics Closes USD$12M Equity Financing

                            Details : This new equity funding that will allow team and play an essential role in initiating three new Phase 2 randomized placebo-controlled clinical studies of Qbeco. Two of these important trials are in critical indications for which there are no effective tr...

                            Brand Name : Qbeco SSI

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 21, 2022

                            Lead Product(s) : Qbeco

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

                            Details : The purpose of the RESTORE trial was to investigate the effect of QBECO SSI treatment on endoscopic and histologic healing in people living with moderate-to-severe Crohn’s disease.

                            Brand Name : QBECO SSI

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2021

                            Lead Product(s) : QBECO SSI

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Qu Biologics Inc

                            Canada arrow
                            PackExpo
                            Not Confirmed

                            Qu Biologics Inc

                            Canada arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QBKPN

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : NRC IRAP

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            QU Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platf...

                            Details : This help will expedite the clinical development & deployment of QBKPN for significant unmet need for broad innate immune protection of the lungs, particularly in vulnerable populations such as the elderly & those with co-morbid conditions who lack innat...

                            Brand Name : QBKPN

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : QBKPN

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : NRC IRAP

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth